Trending stocks

Wai Yuen Tong Medicine Holdings Ltd revenue jumped on 106% in 2015 and EBITDA Margin decreased slightly on 0.51 pp from -5.0% to -5.5%

30/06/2015 • About Wai Yuen Tong Medicine Holdings Ltd ($897) • By InTwits

Wai Yuen Tong Medicine Holdings Ltd reported FY2015 financial results today. Overall the company's long term financial model is characterised by the following facts:
  • Wai Yuen Tong Medicine Holdings Ltd doesn't have a profitable business model yet: FY2015 ROIC is -37.5%
  • The company operates at negative EBITDA Margin: -5.5%
  • EBITDA Margin is quite volatile: -5.5% in FY2015, -5.0% in FY2014, 2.7% in FY2013, 4.7% in FY2012, 9.9% in FY2011
  • Wai Yuen Tong Medicine Holdings Ltd motivates its personel by high Stock Based Compensation (SBC): average SBC/Revenue for FY2011-FY2015 was 0.0%. On average EBITDA Margin was -0.2% for the sames years0
  • Wai Yuen Tong Medicine Holdings Ltd has low CAPEX intensity: 5 year average CAPEX/Revenue was 1.3%. At the same time it's a lot of higher than industry average of 4.7%.
  • CAPEX is quite volatile: 31.8 in FY2015, 8.5 in FY2014, 6.1 in FY2013, 4.1 in FY2012, 19.7 in FY2011
  • The company has unprofitable business model: ROIC is at -37.5%
  • It operates with high leverage: Net Debt/EBITDA is 3.5x while industry average is 0.3x
Below you can find a comprehensive analysis of the key data driving the company's performance and stock price.

Wai Yuen Tong Medicine Holdings Ltd ($897) key annual financial indicators

mln. HKD201120122013201420152015/2014
P&L
Revenue7356629658641,776105.6%
Gross Profit110897122-23-203.5%
SG&A88
EBITDA733126-43-98126.4%
Net Income553326-48-117142.7%
Balance Sheet
Cash656650267189-29.4%
Short Term Debt796749333874.5%
Long Term Debt000178174-2.0%
Cash flow
Capex2046932273.7%
Ratios
Revenue growth15.4%-9.9%45.9%-10.5%105.6%
EBITDA growth45.5%-57.6%-15.8%-266.4%126.4%
Gross Margin15.0%13.5%7.4%2.5%-1.3%-3.8%
EBITDA Margin9.9%4.7%2.7%-5.0%-5.5%-0.5%
Net Income Margin7.5%5.0%2.7%-5.6%-6.6%-1.0%
SG&A, % of revenue4.9%4.9%
CAPEX, % of revenue2.7%0.6%0.6%1.0%1.8%0.8%
ROIC38.0%13.6%9.3%-16.9%-37.5%-20.6%
ROE50.2%24.9%13.8%-28.2%-137.3%-109.2%
Net Debt/EBITDA0.2x0.0x-0.1x0.0x

Revenue and profitability


Wai Yuen Tong Medicine Holdings Ltd's Revenue surged on 106% in FY2015. Having declining revenue the company managed to increase EBITDA margin. EBITDA Margin increased on 4.2 pp from 18.0% to 22.2% in 2015.

Gross Margin decreased on 3.8 pp from 2.5% to -1.3% in FY2015.

Net Income marign decreased slightly on 1.0 pp from -5.6% to -6.6% in FY2015.

Capital expenditures (CAPEX) and working capital investments


In FY2015 the company had CAPEX/Revenue of 1.8%. The company showed small growth in CAPEX/Revenue of 1.2 pp from 0.62% in FY2012 to 1.8% in FY2015. Average CAPEX/Revenue for the last three years was 1.1%.

Return on investment


The company operates at negative ROIC (-37.54%) and ROE (-137.34%). ROIC dropped on 20.6 pp from -16.9% to -37.5% in FY2015. ROE dropped on 109 pp from -28.2% to -137% in FY2015.

Leverage (Debt)


Company's Net Debt / EBITDA is 3.5x and Debt / EBITDA is . Net Debt / EBITDA didn't change in FY2015. Debt surged on 14.4% in FY2015 while cash dropped on 29.4% in FY2015.

Appendix 1: Peers in Pharmaceuticals


Below we provide Wai Yuen Tong Medicine Holdings Ltd benchmarking against other companies in Pharmaceuticals industry for the last 5 years. We show data for the top-5 companies by key financial metric together with the median value for all the companies in the industry.

Top companies by Revenue growth, %

Top 5 FY2011 FY2012 FY2013 FY2014 FY2015
Hong Kong Life Sciences and Technology Group Ltd ($8085)-10.0%-45.4%1,636.5%-52.9%
Northeast Tiger Pharmaceutical Corp Ltd ($8197)-17.7%15.1%-99.9%480.0%
United Gene High-Tech Group Ltd ($399)-71.8%-60.5%196.0%14.2%
China Traditional Chinese Medicine Co Ltd ($570)3.1%22.3%35.2%90.0%
Dragonite International Ltd ($329)-8.8%-10.5%13.5%64.8%
 
Median (38 companies)18.0%14.3%13.5%16.3%-43.6%
Wai Yuen Tong Medicine Holdings Ltd ($897)-9.9%45.9%-10.5%105.6%


Top companies by Gross margin, %

Top 5 FY2011 FY2012 FY2013 FY2014 FY2015
Jilin Province Huinan Changlong Bio-pharmacy Co Ltd ($8049)83.9%82.0%81.5%80.9%
Consun Pharmaceutical Group Ltd ($1681)75.5%75.7%79.1%78.3%
Sino Biopharmaceutical Ltd ($1177)78.5%78.5%77.5%76.4%
China Health Group Inc ($8225)38.7%43.4%33.6%76.2%
Hua Han Bio-Pharmaceutical Holdings Ltd ($587)72.6%65.2%77.9%72.1%
 
Median (36 companies)38.0%39.1%37.2%48.7%39.6%
Wai Yuen Tong Medicine Holdings Ltd ($897)15.0%13.5%7.4%2.5%-1.3%


Top companies by EBITDA margin, %

Top 5 FY2011 FY2012 FY2013 FY2014 FY2015
Asia Resources Holdings Ltd ($899)3.5%-80.8%25.1%113.7%
Pak Fah Yeow International Ltd ($239)28.7%33.9%28.4%52.4%
Real Nutriceutical Group Ltd ($2010)45.6%42.8%43.4%46.0%
China Shineway Pharmaceutical Group Ltd ($2877)47.8%37.8%40.1%40.5%
Lijun International Pharmaceutical Holding Co Ltd ($2005)6.2%21.5%35.9%38.9%
 
Median (37 companies)17.4%19.6%18.8%20.8%-8.9%
Wai Yuen Tong Medicine Holdings Ltd ($897)9.9%4.7%2.7%-5.0%-5.5%


Top companies by CAPEX/Revenue, %

Top 5 FY2011 FY2012 FY2013 FY2014 FY2015
Northeast Tiger Pharmaceutical Corp Ltd ($8197)0.2%11,100.0%103.4%
Extrawell Pharmaceutical Holdings Ltd ($858)5.7%1.7%20.6%92.4%3.6%
Asia Resources Holdings Ltd ($899)12.2%4.4%8.1%92.0%
Lijun International Pharmaceutical Holding Co Ltd ($2005)19.5%16.8%52.4%39.6%
Hao Wen Holdings Ltd ($8019)6.4%30.0%2.3%38.2%
 
Median (37 companies)10.3%8.3%8.1%7.4%3.6%
Wai Yuen Tong Medicine Holdings Ltd ($897)2.7%0.6%0.6%1.0%1.8%


Top companies by ROIC, %

Top 5 FY2011 FY2012 FY2013 FY2014 FY2015
Jilin Province Huinan Changlong Bio-pharmacy Co Ltd ($8049)18.5%16.7%20.8%33.0%
Sino Biopharmaceutical Ltd ($1177)19.9%26.2%26.8%26.5%
Lee's Pharmaceutical Holdings Ltd ($950)31.3%26.1%22.0%22.4%
Shandong Luoxin Pharmaceutical Group Stock Co Ltd ($8058)34.4%27.6%22.2%19.9%
CSPC Pharmaceutical Group Ltd ($1093)9.9%14.5%12.8%18.1%
 
Median (38 companies)8.4%11.6%7.8%10.0%-8.5%
Wai Yuen Tong Medicine Holdings Ltd ($897)38.0%13.6%9.3%-16.9%-37.5%


Top companies by Net Debt / EBITDA

Top 5 FY2011 FY2012 FY2013 FY2014 FY2015
China NT Pharma Group Co Ltd ($1011)0.4x7.2x
United Laboratories International Holdings Ltd/The ($3933)4.4x6.5x4.6x4.2x
Lansen Pharmaceutical Holdings Ltd ($503)0.9x1.7x2.8x3.4x
China Grand Pharmaceutical and Healthcare Holdings Ltd ($512)2.5x5.4x4.0x3.4x
Shandong Xinhua Pharmaceutical Co Ltd ($719)1.4x3.5x3.4x2.8x
 
Median (31 companies)-0.4x0.1x-0.1x-0.5x9.9x